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Abstract
Over the past few years, microRNAs (miRNAs) have not only emerged as integral regulators of gene expression at
the post-transcriptional level but also respond to signalling molecules to affect cell function(s). miRNAs crosstalk
with a variety of the key cellular signalling networks such as Wnt, transforming growth factor-β and Notch,
control stem cell activity in maintaining tissue homeostasis, while if dysregulated contributes to the initiation and
progression of cancer. Herein, we overview the molecular mechanism(s) underlying the crosstalk between Wnt-
signalling components (canonical and non-canonical) and miRNAs, as well as changes in the miRNA/Wnt-signalling
components observed in the different forms of cancer. Furthermore, the fundamental understanding of miRNA-
mediated regulation of Wnt-signalling pathway and vice versa has been significantly improved by high-throughput
genomics and bioinformatics technologies. Whilst, these approaches have identified a number of specific miRNA(s)
that function as oncogenes or tumour suppressors, additional analyses will be necessary to fully unravel the links
among conserved cellular signalling pathways and miRNAs and their potential associated components in cancer,
thereby creating therapeutic avenues against tumours. Hence, we also discuss the current challenges associated
with Wnt-signalling/miRNAs complex and the analysis using the biomedical experimental and bioinformatics
approaches.
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Background
The Wnt pathway is a highly regulated signalling path-
way that controls numerous stages of animal develop-
ment and tissue homeostasis. The Wnt proteins
comprise a highly conserved and diverse family of genes
found in humans, mice, Xenopus, Zebrafish and Dros-
ophila [1] The pathway is closely regulated at both
transcriptional-level regulations to post-translational
modification; thus aberrant Wnt activity often results in
developmental disorders and diseases including but not
limited to cancer [2–4]. For example, during metastatic
processes, epithelial cancer cells require certain charac-
teristics such as elevated expression of mesenchymal
markers as well as other alterations in their microenviron-
ment to enable invasion of adjacent tissues and progres-
sion to metastatic high-grade tumours. Inappropriate Wnt
signals coupled with a loss of E-cadherin promotes an in-
crease in cytoplasmic and nuclear β-catenin levels where
it interacts with the epithelial-mesenchymal transition
(EMT) regulators, such as E-cadherin repressors: Snail,
twists and Zebs [5, 6]. MicroRNAs (miRNAs) are com-
posed of ~22 nucleotide sequences in length and belongs
to the class of non-coding endogenous small RNAs that
are integral post-transcriptional regulators of the gene
expression via direct interaction with the 3’un-translated
region (UTR) of the target messenger RNAs [7]. Recent
advances in biomedical research have allowed experimen-
tal and bioinformatics approaches to identify short non-
coding RNAs such as microRNAs (miRNAs) as regulators
of components of the Wnt-signalling pathways and vice
versa. Thus, both miRNAs and Wnt-signalling pathways
form a network involved in the regulation of key biological
processes.
Main text
Canonical Wnt-signalling
The canonical Wnt-signalling cascade refers to the
transduction of series of signals mediated via the inter-
action of specific Wnt ligands with their target receptor
resulting in the accumulation of β-catenin (Fig. 1a).
Amassment of β-catenin plays a crucial role as the cen-
tral transducer in the activation of downstream factors
[8]. The cytoplasmic stability of β-catenin is usually
maintained at a minimal level by the destruction com-
plex composed of a scaffold combination of tumour
suppressor protein adenomatous polyposis coli (APC),
Axin2, casein kinase1 (CK1) and glycogen synthase kin-
ase 3β (GSK-3β) [9]. Aberrant Wnt/β-catenin signalling
Fig. 1 a Representation of Canonical Wnt/β-catenin pathway. OFF- State: β-catenin is regulated by the destruction complex in the absence of
Wnt ligands. GSK-3β and CK1 facilitates the phosphorylation of β-catenin at specific serine and threonine sites rendering it a target for proteoso-
mal degradation by β-TRCP. As a result of this degradation, β-catenin is prevented from translocating into the nucleus prompting Groucho
(co-repressor) to be bound to TCF thereby repressing gene transcription. ON- State: Once binding of Wnt ligand to Fzd and LRP5/6 co-receptors
occurs, Dvl-fzd complex is formed resulting to the phosphorylation of LRP5/6 by GSK-3β and triggering the recruitment of Axin2 from the
destruction complex. The disassembly of the complex promotes stabilization and accumulation of cytoplasmic β-catenin which eventually
translocate to the nucleus where Groucho is dislodged and TCF is converted into a transcription factor ensuring the transcription of many genes
including c-Myc, Ascl2, cyclin D1 which are essential stem cell regulators as well as mediators of proliferation and differentiation. b Schematic of
Non-Canonical Wnt pathway. In the PCP pathway, Fz activates Dvl through G-proteins in the absence of LRP receptors. Subsequent activation of
the Rho GTPases, Rho and Rac results to the induction of cytoskeletal changes. In the Wnt/Calcium pathway, Dvl activates protein kinase C (PKC)
and the release of intracellular calcium and calcium/calmodulin-dependent protein kinase II (CaMKII) which in turn activates the release of NFAT
and NFkB. NFAT and NFkB subsequently translocate into the nucleus to transcribe regulatory genes that govern cell migration. It is still unclear
whether G-proteins are involved in this particular pathway. Adapted from [209]
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is a common hallmark of malignant CRC cells hence,
mutations in any of the components of the destruction
complex can potentially result to cytosolic β-catenin ac-
cumulation and subsequent activation of Wnt target
genes that drive proliferation [10, 11].
In the absence of Wnt ligand interaction (OFF-state),
the membrane receptor complex is inactivated, thereby
preventing the clustering of a trimeric complex com-
posed of Wnt ligand/Fzd/LRP receptors and eventually
results to β-catenin ubiquitination and degradation
(Fig. 1a) [11]. Although the Wnt/Fzd/LRP complex
model is widely accepted, the precise mechanism of for-
mation is yet to be fully understood. The current and
widely accepted model suggests that CK1 and GSK-3β
kinases target β-catenin by phosphorylating a set of con-
served threonine and serine residues located in the
amino acid terminus [10, 12]. This phosphorylation oc-
curs simultaneously at specific sites, with Serine 45
(Ser45) N-terminus of β-catenin phosphorylated by CK1
while phosphorylation at Threonine 41 (Thr41), Ser33
and Ser37 sites is carried out by GSK-3β [8, 13]. The
consequence of these series of phosphorylation activities
results in the recruitment of APC to the destruction
complex. The APC protein forms a synergy with other
components of the destruction complex and mediates
the degradation of cytoplasmic β-catenin. APC serves a
very important role in the destruction complex due to
its tumour suppressor properties [9, 14], as numerous
scientific evidences show mutations in the APC gene are
not only responsible for familial adenomatous polyposis
(FAP), but also plays a significant rate-limiting role in
the initial stages of majority of sporadic colorectal
cancers [14, 15]. Subsequently, the phosphorylated
regions of β-catenin are exposed to the F-box/WD
repeat protein which is a component of E3 ubiquitin lig-
ase complex β-transducin repeat-containing protein (β-
TRCP) which mediates the ubiquitination and the pro-
teasomal degradation of β-catenin [1]. Once β-catenin is
degraded Wnt target genes fails to be transcribed. This
process keeps the cytoplasmic β-catenin level low
thereby preventing the translocation of β-catenin into
the nucleus.
Conversely, the ON-state of canonical Wnt-signalling
is activated by the binding of Wnt ligands, (secreted
mainly by myofibroblasts beneath the base of the crypts
in the small intestine), to Frizzled and LRP 5/6 co-
receptors at the cell surface [16, 17]. Additionally, stud-
ies show that cancer associated fibroblasts (CAF) is asso-
ciated with the canonical Wnt-signalling pathway [18],
with stromal fibroblasts also implicated in the secretion
of pro-tumourigenic factors that promote skin squamous
cell carcinomas [19]. Formation of this receptor complex
triggers the activation of Dsh/Dvl, a cytoplasmic scaf-
folding protein crucial for Wnt-induced LRP6
phosphorylation [20, 21], which proceeds to inhibit
GSK-3β enzyme activity, triggering a complex series of
events that prevents the phosphorylation and subse-
quent degradation of β-catenin resulting to its conse-
quent stabilization and accumulation in the cytoplasm.
Accumulated cytoplasmic β-catenin then translocate to
the nucleus, where it displaces Groucho (a co-repressor
transcriptional factor) due to its stronger affinity to en-
gage TCF/LEF transcription factors [22, 23] to activate
transcription of target Wnt genes such as c-myc, c-jun,
Axin2, EphB/ephrin-B and CyclinD1. These target genes
all play crucial roles in the regulation of a plethora of
cellular processes including but not restricted to cell
proliferation, cell division, stem cell maintenance as well
as regulation of various stages of embryogenesis [24],
hence a major consequence of dysregulation of β-
catenin could result to maintenance of cancer phenotype
[16, 25–27]. Interestingly, the progression of tumours to
invasive cancers and metastatic disease may also involve
the switch from canonical to non-canonical Wnt-
signalling [28–31].
Non-canonical Wnt-signalling
Apart from the canonical Wnt-pathway, specific Wnt-
ligands can also trigger non-canonical pathways which
are also referred to as β-catenin independent pathways
(Fig. 1b). As earlier mentioned, the Wnt ligands consists
of a large family of 19 secreted glycoproteins that are
cysteine-rich and highly hydrophobic. It is not entirely
understood which particular Wnt ligand participates in
either of the Wnt-pathways, however, some Wnts (such as
Wnt5a and Wnt11) initiate the β-catenin-independent
pathways in a cell-specific independent manner [32]. The
non-canonical Wnt pathways are further divided into
three other distinct branches namely, the Wnt/Ca2+, the
Wnt/JNK and the Wnt/planar cell polarity (PCP) path-
ways (Fig. 1b). The mechanisms of downstream signal
transduction through these pathways is less understood,
although scientific evidences suggest the 3 branches of the
non-canonical pathway function dependently of each
other [13].
Interestingly, the non-canonical Wnt-signalling has
been reported to antagonize the β-catenin-dependent
Wnt-signalling pathway by either or both CaMKII path-
way and NFAT-mediated transcriptional regulation [33],
however, other studies suggest that the PCP pathways
can also antagonize the canonical Wnt cascade [34, 35].
The CaMKII pathway suppresses β-catenin-TCF-
dependent transcription through phosphorylation of
TCF transcription factors [36], while NFAT is reported
to inhibit β-catenin-dependent transcription [37]. All
these findings simply highlight the possible crosstalk
among various types of Wnt-signalling, in addition to
other multiple cell signalling cascades.
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Recent advances to date has strongly cemented the
fact that Wnt-signalling plays crucial roles in normal
biological functions [26, 38]. Supporting scientific evi-
dences over the past decade have successfully identified
various signalling components that have contributed im-
mensely to the establishment of a molecular framework
for the understanding of the different branches of the
Wnt signal transduction pathway, thereby enabling the
correlation and causative relationships between human
diseases and aberrant Wnt-signalling [38–40].
Deregulation of Wnt-signalling activity via genetic
mutations in cancer cells
Generally, cancerous genetic mutations on any gene that
participates in the Wnt/β-catenin signalling cascade
inappropriately reactivate the pathway, leading to
abnormal ON-state activity. In effect, the activity of
Wnt-signalling in the cell is no longer governed by the
presence of Wnt ligands. Therefore, Wnt-signalling may
be switched into the ON-state even in the absence of
Wnt ligand–receptor interaction, leading to the charac-
teristic sequence of ON-state activity: disassembly of the
destruction complex, loss of phosphorylation and deg-
radation of β-catenin and activation of Wnt-induced
gene transcription, which all contributes to cancer pro-
gression. Mutations in CTNNB1, the gene for β-catenin,
have been implicated in colon cancer, gastric cancer, me-
dulloblastoma, melanoma, ovarian cancer, pancreatic
cancer, and prostate cancer [41, 42]. Mutations in APC
gene have frequently been identified in colon cancer as
well, while mutations in AXIN1, the gene for Axin1,
have been identified in hepatocellular carcinoma [43]
and medulloblastoma [44]. Thus, there is considerable
evidence for abnormalities in the Wnt-signalling path-
way in tumorigenesis.
A major consequence of mutations in APC, Axin,
GSK-3β and β-catenin genes is the increased nuclear β-
catenin levels which has already been proven as a hall-
mark of intestinal tumorigenesis. Consequently, mutant
APC protein becomes unable to form a proper destruc-
tion complex with GSK-3β which inevitably impairs the
phosphorylation of β-catenin on specific sites. Similarly,
mutations resulting to amino acid substitutions in the
phosphorylated residues of β-catenin may hinder phos-
phorylation and recognition by the E3 ligase ubiquitin
system thereby prompting the cytoplasmic stabilization
and nuclear translocation of β-catenin [45]. Either form
of disruption eventually promotes nuclear β-catenin ac-
cumulation which ultimately causes abnormal propaga-
tion of Wnt-signalling pathway. In addition, mutation in
β-catenin gene CTNNB1 can ultimately instigate a gain
of function mutation which activates β-catenin, increas-
ing its transcriptional activity and enabling the protein
to evade phosphorylation and subsequent degradation
[46, 47]. Furthermore, mutations also occur in Frizzled
genes resulting in loss of the functional Wnt-receptor
interaction responsible for the initiation of the Wnt-
signalling cascade. These genetic mutations ultimately
prevent the initiation of both canonical and non-
canonical signalling cascade, thus compromising the in-
tegrity of the intestinal epithelium particularly the crypt
base region [48, 49].
Overview of miRNAs biogenesis
MicroRNAs (miRNAs) are composed of ~22 nucleotide
sequences in length and belong to the class of non-
coding endogenous small RNAs. The functions of miR-
NAs in posttranslational gene regulation involves the
direct interaction of miRNA with the 3’ un-translated re-
gion (UTR) of the target messenger RNAs [7, 50]. In
mammals, impartial base pairing between the miRNA
and the target mRNA or gene also results in transla-
tional repression of the target gene [51]. To date, more
than 2500 miRNAs have been identified in the human
genome [52, 53]. The miRNA biogenesis is primarily
mediated by the microprocessor complex composed of
two RNase III endonucleases; Drosha and DGCR8 [52,
54]. In the first step of miRNA biogenesis, miRNAs are
initially transcribed by RNA polymerase II resulting in
the production of primary miRNA (pri-miRNA). Shortly
after transcription and prior to translocation from the
nucleus into the cytoplasm, the pri-miRNA undergoes
modifications and transformation to a ~60–100 nucleo-
tide hairpin structure precursor miRNA (pre-miRNA)
via the activity of Drosha. Once the pre-miRNA is
transported to the cytoplasm by Exportin-5 [7], it
undergoes further modifications by Dicer, a multi-
domain ribonuclease III enzyme. The cleavage event
carried out by Dicer results to final product consisting
of a 22 nucleotide double-stranded miRNA composed
of a mature miRNA strand and its complementary
miRNA strand [55].
Additionally, apart from the canonical miRNA biogen-
esis pathways described above, alternative mechanisms,
particularly through mRNA splicing [56], have been dis-
covered to generate miRNAs or other non-coding RNAs
[57, 58]. The revelation of unconventional miRNA bio-
genesis has been made possible via deep sequencing of
small RNAs from cells deficient in Drosha, Dgcr8 or
Dicer which can be produced in a Dicer-independent or
microprocessor-independent manner.
Alterations of miRNAs/Wnt/β-catenin signalling in cancer
Numerous scientific evidences have implicated miRNAs
as regulators of the Wnt-signalling pathway in the con-
text of embryonic [59], osteoblast differentiation and
bone formation [60, 61] and cardiac development [62,
63]. Bone metastasis occurs due to migration of cancer
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cells from the primary tumours cite to the bone causing
bone alterations such as osteolysis and bone fracture
[64]. Studies have implicated lung, prostate and breast
cancer as the most frequent site of origin of metastatic
cancer accumulation in bone [65, 66]. CXCR4, which is
expressed in malignant breast tumours and human
breast cancer cells have been shown to play a major role
in site-specific metastasis of breast cancers to the bone.
Interestingly, CXCR4 ligand CXCL12/SDF-1α is promin-
ent in bone marrow stromal cells with studies showing
that CXCR4 cooperatively with other factors such as IL-
11, CTGF and OPN facilitate osteolytic bone metastasis
in breast cancer MDA-MB-231 cells [67, 68]. Epithelial-
mesenchymal transition (EMT) is a pathological event
largely associated with tumour metastasis with studies
demonstrating Wnt-signalling through Snail1 and Zeb1
regulates bone metastasis in lung cancer [65]. Addition-
ally, miRNAs such as miR410 have been implicated in
promoting growth, migration and invasion of NSCLC
cells by activating the canonical Wnt-signalling in-vitro
[69]. The network involving both miRNAs and Wnt-
signalling pathway have been implicated in regulating tu-
morigeneses in brain cancer [70], colorectal cancer [59,
71], breast cancer [72], liver cancer [73] and other forms
of cancer [74–78]. For instance, studies carried out on
miR-374a via the use of immunofluorescence staining
technique and subcellular fractionation showed that
miR-374a overexpression resulted in the stabilization
and accumulation of nuclear β-catenin in 4 T1 and
MCF7 breast cancer cell lines [79]. This result suggests
that miR-374a may be responsible for the degradation of
APC or one of the other components of the destruction
complex, hence leading to the translocation of β-catenin
to the nucleus thereby enhancing the transcriptional ac-
tivity of LEF/TCF4 [80].
Another miRNA, miR-200a, has been identified as a
potential negative regulator of the Wnt/β-catenin signal-
ling pathway. This miRNA targets mRNAs of Zeb1 and
Zeb2 which are repressors of E-cadherin. Therefore, by
degrading Zeb1 and Zeb2 mRNA, E-cadherin becomes
abundant and available for binding with β-catenin
thereby forming E-cadherin-β-catenin complex which
promotes cell-cell adhesion [77]. The recruitment of β-
catenin in the formation of this complex is beneficial to-
wards reducing cytoplasmic β-catenin amassment which
would eventually translocate to the nucleus and trigger
the transcription of Wnt target genes [81]. Additionally,
activation of Lin28 has been shown to be necessary for
Wnt-β-catenin pathway mediated let-7 repression and
cell proliferation [82]. Interestingly, let-7 miRNAs have
also been implicated as a potential regulator β-catenin in
cancer cells as overexpression of let-7a in Wnt activated
MDA-MB-231 cells was observed to inhibit β-catenin-
activated cell growth and colony formation, thus
emphasising the significance of let-7 miRNAs as down-
stream regulators of Wnt-β-catenin pathway in the regu-
lation of cell proliferation [83]. Furthermore, miR-34 has
been discovered to attenuate the canonical Wnt-
signalling via corporation with p53 in A549 and MCF-7
carcinoma cell lines. Knockdown and/or deletion of
functional miR-34a gene resulted in the increased ex-
pression of WNT1, LRP6 and β-catenin mRNA in these
cells [84]. The significance of the above findings is that
β-catenin deregulation is a major hallmark of cancer.
These results all suggest that miR-34, miR-320, miR-200
and Let-7 could be exploited for the development of
therapeutic agents with specific focus on targeting the
canonical Wnt-signalling pathway in cancer.
Wnt/miRNA network in the regulation of cancer stem cells
The controversial cancer stem cell (CSC) theory is based
on the phenomenon that cancer cells may be derived
from a rare population of cells possessing stem cell
properties [85–87]. Experimental evidence from multiple
studies suggests that CSCs possess a variety of biological
properties similar to normal somatic stem cells such as
the self-renewal capability, an integral program for tissue
renewal and regeneration. The Wnt pathway plays cru-
cial roles in the regulation of stem cell/progenitors, cell
self-renewal and maintenance in a plethora of systems
[10]. A major similarity between normal stem cell and
CSCs is the fact that they both function via common sig-
nalling pathways such as Wnt & Notch pathways that
aids in the maintenance of proliferation of stem cells
[86]. In contrast, CSCs are distinctive due to the posses-
sion of several pro-cancer characteristics such as chemo-
resistance and tumourigenic and metastatic activities
that are not exhibited by their normal stem cell counter-
parts (Fig. 2).
Recent studies have established the importance and
significant roles played by the canonical Wnt-signalling
in stem cell self-renewal activities in various tissues and
cell types [88]. For instance, Wnt3a was shown to foster
the formation of embryonic stem cell (ESC)-like colonies
[89]. Canonical Wnt pathway activation was shown to
augment alkaline phosphatase and Cbfa1/Runx2 expres-
sion thereby facilitating mesenchymal stem cells (MSCs)
osteogenic differentiation [90, 91]. Canonical Wnt-
signalling is also crucial for differentiation and mainten-
ance of the intestine as several scientific evidence have
identified the expression of Wnt receptors and ligands
such as LRP5, SFRP5, Wnt3/6, Fzd4/6/7 in epithelial
cells located at the intestinal crypt base [88, 92].
The role of miRNA in the regulation of stemness of
CSCs is another aspect of miRNA activity currently
under investigation. Reports suggest that miR-193a ex-
pression inhibits tumourigenicity and invasiveness by
directly targeting KRAS and plasminogen activator
Onyido et al. Molecular Cancer  (2016) 15:56 Page 5 of 17
urokinase (PLAU), respectively, with these two factors
highly expressed in human colon adenocarcinomas [93].
Also, miR-451 appears to be another regulator of CSC
properties such as drug resistance, self-renewal and
tumourigenicity. Experiments carried out in spheroid
cell cultures, showed reduced expression of miR-451,
triggering the up-regulation of macrophage migration
inhibitory factor (MIF) and COX-2 which are involved
in deregulation of canonical Wnt pathway in CSCs [94,
95]. Another miRNA, miR-34a inhibits Notch signalling
by directly targeting Notch receptors [96], resulting in
an impaired Notch signalling generation of daughter
cells (non-CSCs), whereas low miR-34a levels enhances
Notch signalling and in turn promotes maintenance of
CSCs. Members of the miR-34 family of miRNAs which
have also been implicated as direct targets of p53, act as
tumour suppressors by governing reprogramming
through the suppression of pluripotency genes including
Sox2, Nanog and N-myc [97, 98]. Additionally, the let-7
family, also a negative regulator of β-catenin, is another
crucial modulator of ESC differentiation [99] (Fig. 2).
Cancer-related miRNA modulation of Wnt-signalling
cascade
As critical biological modulators, it is no more news that
miRNAs acts to suppress or facilitate cancer and tumour
development by interacting with targets of the Wnt-
signalling pathway. A summarized description showing
the alterations of miRNAs/Wnt/β-catenin signalling in
cancer has been provided (Table 1). A more detailed ex-
planation on the Wnt/miRNA network in carcinogenesis
has been provided in recent studies [100, 101].
Bioinformatics approaches to study Wnt pathway-
regulated miRNAs and their targets
Following the initial discovery of the association of miRNA
with cancer over more than a decade ago, technological ad-
vances that have produced multiple high-throughput
Fig. 2 Importance of Wnt/miRNA network in the regulation of cancer stem-like cells. The Wnt-signalling (canonical & non-canonical) pathway
governs the activity of some stem cell-specific miRNAs which plays crucial roles in tumour initiation and development. Aberrant Wnt-signalling
could activate oncogenic miRNA expression which in-turn enhances the self-renewal potential of CSCs with subsequent expansion of the CSC
pool which gives rise to cancer cells that possess self-renewing ability, resistance to drug therapy and ability to instigate new tumour growth
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bioinformatics methods designed for profiling miRNA ex-
pression and identification of miRNA targets involved in a
plethora of pathways that regulate normal physiology and
various diseases have being established [53]. Compared
with other nucleic acids, miRNA analysis tends to be intri-
cate due to several factors ranging from their short length,
ability to discriminate between primary and mature forms
and highly conserved sequences within family members.
Notwithstanding, the evolution of Next-generation sequen-
cing (NGS) platforms which allows for the simultaneous
discovery of new miRNAs and confirmation of known miR-
NAs, overcome the limitations presented by microarrays
and other traditional methods used for miRNA profiling
[102, 103]. NGS effectively reduces the burden of genome
sequencing by enabling the identification of characteristic
expression level and splicing variants within the transcrip-
tome [104, 105], characterization of DNA-protein inter-
action [106, 107] and understanding the role epigenetics
plays in normal and diseased state [108, 109].
The challenging enormity of tumour heterogeneity,
both in the primary tumour and metastasis has become
explicit. Although, individual interactions between com-
ponents of the canonical Wnt pathway and miRNAs in
normal and cancer state have already been established
[59, 71, 110, 111], we have simply just began to compre-
hend the role of miRNAs, not only in normal human de-
velopment but also in tumour progression mediated by
the canonical Wnt-signalling and vice-versa especially
due to the fact that multiple components are involved in
this complex network. Therefore, more efforts are re-
quired to identify the mechanism that controls miRNA/
canonical Wnt-signalling network. As a result, bioinfor-
matics strategies that provide a comprehensive, genome-
wide identification of Wnt/β-catenin-regulated miRNAs
and their associated target genes as well as other tran-
scription factors that cross-talk with the pathway must
be employed. The bioinformatics strategy adopted to
execute this approach involves the identification of Wnt/
β-catenin-regulated miRNAs or vice-versa and the
identification of down-stream target mRNAs of the
Wnt/β-catenin-regulated miRNAs undertaken via gene
sequence complementarity. At the moment, numerous
pilot projects comprising of cancer genomes have being
undertaken using NGS in clinical research, mainly with
the aim of identifying oncogenic mutations that can be
exploited by mutation-specific drugs which would be
useful for personalized medicine [112].
In the following section we will briefly describe the dif-
ferent bioinformatics approaches that have been utilized
in recent advances to identify and characterize Wnt/β-
catenin-regulated miRNAs and their associated targets
as well as the experimental strategies equally used for
the validation of bioinformatics data (Fig. 3).
ChIP-sequencing
Recent advances in next-generation DNA sequencing
combined with chromatin immuno-precipitation (ChIP-
Seq) have provided methods ideal for identification of
transcription factor binding sites (TFBSs) with excep-
tional sensitivity as well as predicting mRNA targets of
miRNA [113]. ChIP has a reputation for being the gold
standard technique for the identification of a target gene
of various transcription factors [114, 115]. Technological
advancement in ChIP studies allows investigators the
luxury to utilize ChIP assay for the recognition and
characterization of the entire binding sites for a particu-
lar transcription factor (Fig. 4). For instance, using the
ChIP-Seq approaches, recent studies have identified
Table 1 Alterations of miRNAs/Wnt/β-catenin signalling in cancer
Cancer type miRNA Wnt-signalling target(s) Inhibits/activates carcinogenesis References
Colorectal miR-224 cdc42 Inhibits [100]
Colorectal miR-574-5p Qki6/7, p27, β-catenin Activates [214]
Colorectal miR-7,miR-34 Ying Yang Activates [215, 216]
Colorectal miR-29b BCL9 Inhibits [217]
Liver miR-155, miR-106b APC Activates [218, 219]
Liver miR-148b, miR-122 Wnt1 Inhibits [220, 221]
Liver miR-139 TCF4 Inhibits [222]
Breast miR-31, miR145 RhoA, β-catenin, c-myc Inhibits [223, 224]
Breast miR-142 APC Activates [164]
Prostate miR320 β-catenin Inhibits [225]
Lung miR-191 Wnt1 Activates [226]
Thyroid miR-146b-5p ZNRF3 Activates [227]
Ovarian miR-181a VNGL1 Activates [228]
Oesophageal miR-141 SOX17 Activates [229]
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1250 overlapping putative target genes co-regulated by
both TCF4 and STAT3 in gliomas [116]. TCF4, a
member of the Tcf/Lef family and ubiquitously expressed in
the colon epithelium, forms a complex with β-catenin with
subsequent binding to promoter regions of specific genes
that trigger processes crucial for normal development and
in abnormal conditions, drive tumour progression [117,
118]. In recent times, miRNAs have been identified as one
of the factors that possess the ability to modulate biological
networks, including Wnt/β-catenin/TCF4 signalling. For
instance, using IEC-6 cell nuclear extracts, putative binding
sequences within the miR-30e promoter region were
Fig. 3 Bioinformatics pathway for the characterization of Wnt-signalling regulated miRNAs and their targets. Summary of a proposed stepwise
bioinformatics approach for the characterization of Wnt-regulated miRNAs. Due to the fact that canonical Wnt pathway is driven by several
components; key components such as β-catenin can be utilized to identify potential miRNA regulators. Programmes and tools such as Benjamin-Hochberg
[210], iCLIP [211], miRDeep [212] have all been used to perform bioinformatics analysis for different experiments. Image adapted from [213]. Note: β-
catenin is a major transducer in the canonical Wnt-signalling pathway hence; the proposed stepwise bioinformatics approach can be applied to the
study of network of miRNA and other key components of either the canonical or non-canonical signalling pathway
Fig. 4 Flow chart illustrating the steps involved in the ChIP-Seq procedure
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discovered, via ChIP assay, to actively bind beta-catenin/
TCF4 with experiments suggesting miR-30e as a potential
downstream target for the β-catenin/TCF4-mediated intes-
tinal cell differentiation [119]. Further characterization
using miRBase Sequence Database identified the conserved
sequence of 5′-UGUAAACAUCCUUGACUGGAAG-3′ in
mature miR-30e sequences derived from human, mouse,
and rat. Additionally, the binding properties of β-catenin/
TCF4 with miR-30e were validated and confirmed by per-
forming EMSA and super-shift assay.
Similarly, ChIP experiments carried out in mESCs and
P19 cells showed that Tcf3 binds directly to the miR-302
promoter regions to repress the transcription of the miR-
302 gene [120], thus suggesting miR-302 gene is transcrip-
tionally regulated via the Wnt/β-catenin pathway. Tcf3, a
member of the Tcf/Lef family comprised of Tcf1, Tcf3,
Tcf4 and Lef1 transcription factors mainly acts as a tran-
scriptional repressor of the canonical Wnt-signalling by
competing for β-catenin binding sites [121].
As previous studies have implicated mutations of APC,
CTNNB1 and TCF4 genes and other components of the
Wnt-signalling pathway as key oncogenic drivers in dif-
ferent forms of cancers [122, 123], applications of ChIP-
Seq would be beneficial in providing a genome-wide
binding profile of components of this pathway in other
to identify potential miRNA genes that may be co-
regulated by the Wnt-signalling pathway and exploited
for therapeutic purposes [124]. Importantly, in the field
of epigenetics, utilization of ChIP-Seq can also provide a
platform with which epigenetic profiles through the
study of primary cells and tissues can also be generated
via identification of genome-wide profiles of DNA
methylation, nucleosome positioning and histone modi-
fications. This would provide a better understanding to
the epigenetic machinery and alterations in the epigen-
etic landscape that occur in cancer compared with nor-
mal cells, the roles of these changes in cancer initiation,
progression, metastasis and the potential use of this
awareness in designing more effective therapeutic treat-
ment strategies [125].
There have been several recent papers detailing ChIP-
Seq limitations, for examples difficulty in transferring
and maintaining data due to the large file sizes [126],
and identifying regions enriched in the sample through
the use of peak callers [127] that appears to be due to
the presence of three types of regions namely, sharp,
broad, and mixed. These shortcomings, can however be
abolished by the development of more user-friendly soft-
ware analysis tools in the near future.
miRNA expression profiling
The comprehensive and efficient study of miRNA ex-
pression profiling has been made convenient via the evo-
lution of next generation sequencing technologies. Our
understanding of the regulatory roles of miRNAs in gene
expression, and association with diseases triggering mul-
tiple changes in gene expression levels facilitating cancer
and tumour progression has been improved upon by ad-
vances in miRNA expression profiling research [128],
which could also be derived from miRNA seq (Fig. 3).
Although high-throughput platforms such as microarray
hybridization and real-time reverse transcription PCR
have shown to be authentic tools and are still applicable
in current research, next generation sequencing (NGS)
technology has established itself as the most preferred
and efficient platform for miRNA expression study as it
possesses the ability to identify novel miRNAs that are
beyond the capabilities of traditional methods [129].
Identification of Wnt-regulated miRNAs through ex-
pression profiling methods can be achieved by enforced
expression of the Wnt ligand which consequently results
to the subsequent activation of both or either canonical or
non-canonical Wnt-signalling pathways depending on the
type of Wnt ligand. Specifically, expression levels of indi-
vidual components that are crucial to the progression of
the cascade such as APC, β-catenin and Tcf4 transcription
factors can be matched with different miRNAs with the
aim of observing patterns of miRNAs regulated by the
Wnt pathway. For instance, characterization of non-
coding transcriptomes of tissues derived from six normal
pancreas and pancreatic cancer (PDAC) tissues using
high-throughput NGS-based technology algorithms such
as small RNA-sequencing (sRNA-Seq) and Massive Ana-
lysis of cDNA Ends (MACE) identified miR-802 as a nega-
tive regulator of TCF4 [130], which upon binding to β-
catenin triggers the expression of Wnt target genes. Inter-
estingly, using omiRas [131], TCF4 was observed to con-
tain three mir-802 binding sites in its 3′ UTR with
additional validation experiments revealing a significant
correlation with Zeb1 and miR-21. Several studies have
also confirmed Zeb1 as a key Wnt target [132, 133] as well
as identification of miR-802 as a potential tumour sup-
pressor via NGS techniques [134]. Some other popular
NGS miRNA databases that can be beneficial in carrying
out miRNA expression profiling for identification of Wnt
target genes includes, but not restricted to: deepBase
[135], miRGen 2.0 [136], miRBase [137], miRExpress
[138] and CLIPseqtools [139].
Notwithstanding, traditional platforms for the execu-
tion of miRNA expression profiling have also been use-
ful in identifying miRNA targets of the Wnt-signalling
pathway and vice-versa. In colorectal cancer, global
miRNA expression profiling carried out on 13 cancer
and adjacent normal samples showed a significant
down-regulation of 61 and up-regulation of 42 miRNAs
with enrichment in pathways promoting tumour pro-
gression such as the Wnt pathway in addition to TGF-β
and MAPK pathways [140]. Also, following differential
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miRNA expression profiling of HepG2 under varying
conditions and validations performed by RT-PCR, 9
miRNAs, including miR-34a was observed to be differ-
entially expressed following AFB1 treatment [141].
Aflatoxin-B1 (AFB1) is a hepato-carcinogenic mycotoxin
that induces hepatocellular carcinoma [142–144]. Mean-
while, separate studies have implicated miR-34a as a
tumour suppressor and negative regulator of the Wnt-
signalling pathway [59, 145, 146].
A major limitation/complication of miRNA expression
profiling includes the recent discovery of isomiRNAs
that tend to display sequence variations by shortening or
lengthening of the 3’ end [147, 148]. Unfortunately, re-
cent studies have identified over 3300 miRNA variants
with the most abundant miRNA sequence different from
the miRBase sequence [149]. Additionally, miRNA end
heterogeneity can influence the accuracy and consistency
of quantifying miRNA expression levels. Due to the
heavy reliance of qPCR and microarrays on the accuracy
and availability of miRBase sequences for probe and pri-
mer design, mutations may contribute to difficulty in
miRNA detection [148].
CLIP/miRNA sequencing
Crosslinking and immunoprecipitation sequencing (CLIP-
Seq) offers the luxury of analysing RNA/protein inter-
action. This approach is similar to RIP-Seq, however,
stabilization of protein-RNA complexes are achieved by
ultra-violet (UV) crosslinking. UV crosslinking is used as
an ideal crosslinking agent in RNA studies due to the in-
ability for UV crosslinks to form between proteins. miR-
NAs are subsequently reverse transcribed to cDNA and
analysed with sequencing (RNA-Seq) for mapping of
miRNA binding sites on their target mRNAs with high
confidence [150]. These sets of sequenced miRNA target
and pathway genes are subsequently screened to identify
its associated biological pathways for a comprehensive un-
derstanding of their biological function.
CLIP-Seq and target prediction studies effectively
identify individual mRNAs regulated by multiple miR-
NAs, therefore proving that the transcriptional regula-
tion of a single gene may be dependent on the combined
effect of multiple miRNAs. Next-generation sequencing
of RNA (RNA-Seq) allows for the generation of tissue-
specific gene expression profile data which can be useful
in developing a novel pathway analysis methodology for
the prediction of miRNA function. Some web applica-
tions used for the identification of miRNA-regulated
pathways in a tissue specific manner include miTALOS
v2 [150], ToppMir [151] and miRGator [152].
Although experimental studies focused specifically on
the identification of miRNAs that regulate the Wnt-
signalling pathway are scarce, pathway analysis using
CLIP-Seq of the miR-200 cluster family (miR-200b/c/
miR-429 and miR-200a/miR-141) which has been estab-
lished to be involved in cell migration and EMT, was
able to identify a connection between miR-200b/c/miR-
429 and the Wnt-signalling pathway in hepatocellular
carcinoma (HCC) and liver fibrosis tissue samples [150].
Additionally, miR-199a/b-3p was also implicated to be
involved in EMT, cell migration and metastasis through
cytoskeletal re-organization. Interestingly, this was in
agreement with previous studies describing the involve-
ment of miR-199 in EMT [153, 154].
A major limitation of CLIP-Seq however is the inabil-
ity to reduce background noise/signals due to the nature
of high-throughput sequencing. For instance, Matthew
et al. [155] reported the difficulties in eliminating cross-
linked background containing T > C conversions by bio-
informatics analysis. Another bottleneck is the low RNA
output efficiency inevitably due to the loss of RNA con-
tent and low cross-linking efficiency during the experi-
mental process [156].
Validation and follow-up experiments
Following the elucidation of Wnt-mediated regulation of
miRNAs or vice versa, potential candidate targets are
confirmed and validated by additional experimental ana-
lyses that interrogate the pathological and physiological
implications of the discovered regulations. These valida-
tions can be performed via two conventional strategies:
an approach involving the exposure of a tumour tissue/
sample to genetically altered oncogenic candidates, or an
approach which involves the systematic manipulation of
oncogenic candidates into becoming wild-type tissues
[157]. The latter can be further modified by introducing
the oncogenic or tumour suppressor candidate into a
different mouse model (immunocompetent of immuno-
compromised) for the purpose of gain of function and
loss of function studies on a potential miRNA target.
CRISPR/Cas9 System
Gain-and-loss-of-function studies are one of the most
efficient approaches employed to validate the oncogenic/
tumour suppressor potential of a target gene following
NGS methodologies. However, in comparison to the
relative potency of numerous overexpression strategies,
the methodologies developed for miRNA downregula-
tion appear to be less robust [158, 159]. More recently,
the CRISPR (clustered regularly interspaced short palin-
dromic repeats) became a well-recognized genome edit-
ing tool, referred to as CRISPR-associated endonuclease
(Cas9) system [160]. CRISPR consists of short palin-
dromic repeat sequences interspacing with spacers
adjacent to associated endonucleases, such as Cas9.
Considering the difficulties in contemporary methodolo-
gies in miRNA silencing versus the versatility and flexi-
bility of CRISPR/cas9 system in gene editing, CRISPR/
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cas9 should easily be an unorthodox strategy in the
regulation of miRNA expression [159].
For instance, using HT29 and HCT116 CRC cells trans-
fected CRISPR/cas9 vectors were able to reduce the ex-
pression levels of mature miR-200c as well as miR-141
and miR-17 by 96 % [159], with recent evidences implicat-
ing miR200 as a key modulator of canonical Wnt-
signalling [70, 161, 162]. This supports the hypothesis that
CRISPR/cas9 system can be a suitable tool for miRNA
loss-of-function validation studies following bioinformat-
ics analysis. Furthermore, following transcriptional profil-
ing of MV4-11 B-myelomonocytic leukaemia cell lines
using RNA sequencing, CRISPR/cas9 technologies en-
abled the validation of miR-150 as a bonafide oncogenic
promoter of leukemic cell proliferation and growth
through targeting of p53 [163]. This is also consistent with
previous studies suggesting that the activation of canonical
Wnt-signalling pathway and miR-150 in human breast
cancer stem cells (BCSCs) is modulated by miR-142 [164].
Similarly, microRNA profiling analyses in conjunction
with CRISPR/Cas9 systems have been utilized to validate
candidate novel transcription factors including miR-199
which was revealed as an oncogenic activator involved in
Pancreatic ductal adenocarcinoma (PDAC) pathogenesis
[165]. Here in, analysis of miR-199 functional significance
in pancreatic cancer further showed induction in migra-
tion, invasion and proliferation triggered by miR-199 in-
hibition of FOXA2. This is also in agreement with
previous study suggesting miR-199 targets several key dif-
ferentiation and cell proliferation regulatory factors gov-
erning the Wnt-signalling pathway, such as fzd4 [166]. All
the above mentioned examples are a testament to the ever
increasing relevance of the CRISPR/Cas9 system in the
validation of specific miRNAs involved in, but not re-
stricted to the Wnt-signalling pathway in cancer and
tumour progression.
Despite the outstanding potential of CRISPR/Cas9 in
transcription regulation, genome editing and gene therapy,
some important issues, such as off-target mutations [167],
PAM dependence [168] and gRNA production [169], all
provides a bottleneck to the efficiency of system. Several
miRNAs reside in the introns of their pre-mRNA host
genes and share common regulatory elements, primary
transcripts, resulting to similar expression profile patterns.
This makes it difficult to distinguish the functional effects
arising from both the miRNA silencing and host gene si-
lencing. Nevertheless, alteration of the first 20 nucleotide
sequences of the gRNA to hybridize to target DNA se-
quence can be utilized to distinguish the functional ef-
fects of miRNA genes transcribed from their own
promoters [170]. Although DNA and RNA injection-
based techniques such as inoculation of CRISPR
components as RNA and plasmids expressing gRNA
and Cas9 is possible, more attention should still be
focussed on development of novel robust delivery
methods for CRISPR/Cas9 system [171].
Genetically engineered mouse models (GEMMs)
The use of genetically engineered mouse models
(GEMMs) can also provide an avenue for the validation of
miRNAs involved in the regulation of Wnt-signalling
pathway following bioinformatics analysis. Although there
exist some differences between humans and mice, new
models possess the ability to accurately mimic erratic hu-
man malignancies and tumour development, thus enab-
ling efficient tracking of both primary and metastatic
tumour progression from initial stages than hitherto pos-
sible [172]. These mouse models have particularly im-
proved our knowledge of cancer initiation, metastasis, and
invasion, tumour angiogenesis as well as the importance
of the myriad of molecular networks observed in human
cancers. The study of loss-of gene function is also applic-
able in mouse models by performing mouse conditional
gene mutation [173], mouse gene knock-outs (KO) [174,
175], mouse single cell knock-outs [176] and mouse
models for RNA interference [177, 178]. Similarly, gain of
gene function studies in mouse models have been success-
fully performed [172], however for the purpose of this re-
view we will specifically focus on mouse models for RNA
interference studies.
To elucidate the importance of miR-184 in modulating
Wnt-signalling in the retina, delivery of formulated
nanoparticle-derived miR-184 in the retina of oxygen-
induced retinopathy (OIR) mice significantly inhibited
Wnt-signalling [179]. OIR is an established model for the
study of vascular pathology in the retina [180, 181]. Add-
itionally, a more recent study utilized the generation of an
endothelial-specific miR-17 ~ 92 cluster knock-out mice by
crossing mice possessing a floxed miR-17 ∼ 92 allele trans-
genic mice expressing Cre-recombinase under the control
of a tamoxifen-inducible CDH5 (VE-cadherin) promoter
[182, 183]. This model enabled the identification of Fzd4
and LRP6 receptors as functionally pertinent miR-19 target
genes with further studies on 17 ∼ 92 KO mice suggesting
miR-17 ~ 92 cluster antagonizes the canonical Wnt-
signalling cascade [183]. In separate studies, the existence
of a let-7/Lin28/Wnt-β-catenin signalling network in-vivo
was confirmed using premalignant mammary tissue of
MMTV-Wnt-1transgenic mice [184]. Again, the above
mentioned examples amongst numerous others have high-
lights the relevance of GEMMs as an authentic experimen-
tal approach for the validation of miRNAs as targets of
Wnt-β-catenin signalling pathway following bioinformatics
data analysis.
Intestinal organoid culture
The evolution of tissue engineering have given rise to
organoid culture which is a novel and effective tissue
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stem cell derived three dimensional (3D) model and a
useful tool predominantly for functional study [185,
186]. Basically, glandular organ 3D culture is categorized
into those derived from either a combination of both
mesenchymal and epithelial components from stomach,
colon, liver, lung and small intestines supplemented by
exogenous growth factors [187–189] or specifically from
epithelial cells of gastrointestinal tissue origin [190–192].
Potential applications of organoid models include mainly
functional validation studies such as validation of puta-
tive oncogenic or tumour suppressor genes and cancer
therapeutic validation studies [189, 193, 194]. It is there-
fore not surprising that this model have already been
exploited to validate the Wnt-derived oncogenic and
tumour suppressor properties of miRNAs.
Contextual modelling in APC-deleted colon-derived
organoids overexpressing either miR-483 or Igf2 showed
that enforced miR-483 expression promotes high-grade
dysplasia [193]. Although experimental evidences have
implicated miR-142 as a tumour suppressor in breast
cancer cells in vivo [195, 196], others have suggested
that miR-142 maintains breast cancer stem cells (BCSCs)
by activating the canonical Wnt-signalling pathway
[164]. The ability of miR-142 to modulate organoid for-
mation in BCSCs was further investigated with results
suggesting miR-142-3p as an essential regulator of
organoid formation in murine mammary CSCs [164].
Furthermore, in a separate study, primary mammary
epithelial organoids were derived from axin2/conductin-
lacZ mouse [197] in order to determine whether candi-
date miRs can control Wnt-signalling with results
strongly implicating miR-1 as an inhibitor of Wnt-
signalling pathway in vivo [198]. The relatively rigid
ECM (Matrigel) could serve as a limiting factor by
obstructing drug penetration, thereby hindering the ef-
fectiveness of organoids in drug screens via robust lenti-
viral or miRNA delivery systems. Although organoid
protocols have been established for tissues derived from
various organs [199], more efforts needs to be applied to
the development of organoids culture from tissues
whose niche factors remain poorly understood [200].
Apart from the above mentioned techniques and ex-
perimental designs utilized in the validation of the gene
expression levels and numerous short sequences gener-
ated by NGS platforms, other validation techniques
widely used include quantitative RT-PCR which is often
used for the validation of differentially expressed genes
discovered using microarray and RNA-Seq [201, 202].
Functional validation of novel miRNAs involved in Wnt-
signalling pathway can also be performed via induced
pluripotent stem cells (iPSC) technologies. Although not
used specifically for the validation of miRNA/Wnt-sig-
nalling network in cancer, patient-derived iPSC ap-
proaches [203], have been employed in other studies for
Fig. 5 Schematic overview of benefits of bioinformatics and experimental approaches in understanding miRNA/Wnt-signalling network in cancer
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validation of NGS and other gene sequencing-based
data [204, 205]. Additionally, guidelines for the valid-
ation of clinical data acquired from NGS are also
available to safeguard the standard of clinical NGS
experiments [206–208].
Conclusions
Although the application of bioinformatics in the eluci-
dation of the miRNAs-mediated regulation of Wnt-
signalling is extremely beneficial (Fig. 5), particularly in
the area of cancer research, the significant challenges
that remain still signify the usefulness of experimental
approaches for the analysis and validation of bioinfor-
matics data. The misconception that a dichotomy exists
between bioinformatics and experimental approaches in
cancer research would certainly slow down the rate of
progress in establishing the roles miRNA plays in the
physiology and pathology of the human system. While
bioinformatics strategies may be seen as improvements
to experimental approaches such as the so-called ‘wet
lab experiments’, we cannot deny the fact that experi-
mental approaches are still relevant in modern medicine,
especially in the area of experimental validation. As
already noted in this review, the NGS system still pos-
sesses significant challenges; hence in order to circum-
vent the bottleneck of data storage as well as complex
data analysis, the continual development of methodolo-
gies/algorithms for data analysis and integration is ne-
cessary. Given the ever increasing passion for the
identification of proteomic and genomic biomarkers to
enhance cancer detection at the early stage, utilization of
both bioinformatics and experimental strategies for
miRNA target identification, functional target validation
and their specificity for particular tissues must be
employed. Further investigations of the miRNA/Wnt-
signalling network, in addition to the crosstalk between
miRNAs and other signalling networks implicated in
cancer development must also be performed in order to
boost productive application to improve human health.
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